Anilides
-
Subject Areas on Research
- Activity of androgen receptor antagonist bicalutamide in prostate cancer cells is independent of NCoR and SMRT corepressors.
- An interdomain interaction of the androgen receptor is required for its aggregation and toxicity in spinal and bulbar muscular atrophy.
- Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure.
- Biochemical recurrence after definitive prostate cancer therapy. Part II: treatment strategies for biochemical recurrence of prostate cancer.
- Biochemical recurrence of prostate cancer.
- Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.
- Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
- Cabozantinib in genitourinary malignancies.
- Cabozantinib in ovarian clear cell cancers: UnMET expectations.
- Cabozantinib versus sunitinib as initial therapy for metastatic renal cell carcinoma of intermediate or poor risk (Alliance A031203 CABOSUN randomised trial): Progression-free survival by independent review and overall survival update.
- Clinical results in cachexia therapeutics.
- Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors.
- Design of tenofovir-UC781 combination microbicide vaginal gels.
- Design, synthesis, and pharmacological evaluation of ultrashort- to long-acting opioid analgetics.
- Directed evolution of subtilisin E in Bacillus subtilis to enhance total activity in aqueous dimethylformamide.
- Effects of cabozantinib on pain and narcotic use in patients with castration-resistant prostate cancer: results from a phase 2 nonrandomized expansion cohort.
- Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
- Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate.
- Hedgehog signaling antagonist promotes regression of both liver fibrosis and hepatocellular carcinoma in a murine model of primary liver cancer.
- Hedgehog signaling in human medullary thyroid carcinoma: a novel signaling pathway.
- Isolation, structure and biological activities of platensimycin B4 from Streptomyces platensis.
- Ligand-specific dynamics of the androgen receptor at its response element in living cells.
- Mammalian chymotrypsin-like enzymes. Comparative reactivities of rat mast cell proteases, human and dog skin chymases, and human cathepsin G with peptide 4-nitroanilide substrates and with peptide chloromethyl ketone and sulfonyl fluoride inhibitors.
- Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias.
- N-Acylated Derivatives of Sulfamethoxazole Block Chlamydia Fatty Acid Synthesis and Interact with FabF.
- Neoadjuvant doxil chemotherapy prior to androgen ablation plus radiotherapy for high-risk localized prostate cancer: feasibility and toxicity.
- Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas.
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy.
- Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy.
- Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer.
- Platensimycin and platencin congeners from Streptomyces platensis.
- Previously unreported adverse reaction to encainide.
- Reduction of granulosa cell progesterone secretion in vitro by intraovarian implants of antiandrogen.
- Regulation of the macrophage population in postnatal rat testis.
- Reply to B. Rini et al and S. Buti et al.
- Shigella flexneri dysentery in the Australian forces in South Vietnam.
- Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).
- Treating the biochemical recurrence of prostate cancer after definitive primary therapy.
- Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
- Up-regulation of Hedgehog pathway is associated with cellular permissiveness for hepatitis C virus replication.
- Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.